B. Riley initiated coverage of Nuvation Bio (NUVB) with a Buy rating and $12 price target The firm cites the company’s positive commercial revenue ramp of its lead drug Ibtrozi within mutation-defined lung cancer for the Buy rating. The drug’s “class-leading attributes are supporting robust early launch metrics,” the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVB:
- Positive Outlook on Nuvation Bio’s Safusidenib Driven by Promising Clinical Data and Strategic Focus
- Nuvation Bio Reports Positive Phase 2 Study Results
- Nuvation Bio’s Strategic Dilemma: Navigating Taletrectinib’s Global Commercialization Risks
- Nuvation Bio’s Earnings Call: IBTROZI’s Success Amid Challenges
- Midday Fly By: Palantir reports Q3 beat, Starbucks forms China JV